Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2008-07-01
2008-07-01
Landsman, Robert (Department: 1646)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C530S350000, C424S192100, C424S199100, C435S069700
Reexamination Certificate
active
10404466
ABSTRACT:
The invention provides for DNA encoding Fas ligand muteins and chimeras and the proteins encoded thereby. The invention further includes the use of DNA and vectors to produce transformed cells expressing the mutant or chimeric Fas ligand. When the Fas ligand of the invention is a non cleavable form, the cells expressing the Fas ligand are useful in vitro for identifying Fas expressing cells and in vitro or in vivo for reducing populations of Fas expressing cells. Thus, in other embodiments, the present invention is also directed to a method for treating a patient, for example a mammal, for autoimmune disease or transplant rejection by administering a Fas ligand therapeutic agent. The therapeutic agent is a polypeptide, a polynucleotide encoding the polypeptide or a small molecule. The polypeptides include full-length Fas ligand polypeptide, or a biologically active variant, derivative, portion, fusion or peptide thereof.
REFERENCES:
patent: 4399216 (1983-08-01), Axel et al.
patent: 4405712 (1983-09-01), Woude et al.
patent: 4411648 (1983-10-01), Davis et al.
patent: 4551433 (1985-11-01), DeBoer
patent: 4560655 (1985-12-01), Baker
patent: 4603112 (1986-07-01), Paoletti et al.
patent: 4657866 (1987-04-01), Kumar
patent: 4745051 (1988-05-01), Smith et al.
patent: 4762915 (1988-08-01), Kung et al.
patent: 4767704 (1988-08-01), Cleveland et al.
patent: 4769330 (1988-09-01), Paoletti et al.
patent: 4777127 (1988-10-01), Suni et al.
patent: 4797368 (1989-01-01), Carter et al.
patent: 4837148 (1989-06-01), Cregg
patent: 4853230 (1989-08-01), Lovgren et al.
patent: 4859609 (1989-08-01), Dull et al.
patent: 4861719 (1989-08-01), Miller
patent: 4927762 (1990-05-01), Darfler
patent: 4928555 (1990-05-01), Nuti
patent: 4980289 (1990-12-01), Temin et al.
patent: 5010175 (1991-04-01), Rutter et al.
patent: 5091309 (1992-02-01), Schlesinger et al.
patent: 5139941 (1992-08-01), Muzyczka
patent: 5149655 (1992-09-01), McCabe et al.
patent: 5166057 (1992-11-01), Palese et al.
patent: 5166320 (1992-11-01), Wu et al.
patent: 5173414 (1992-12-01), Lebkowski et al.
patent: 5194392 (1993-03-01), Geysen
patent: 5206152 (1993-04-01), Sukhatme
patent: 5217879 (1993-06-01), Huang et al.
patent: 5219740 (1993-06-01), Miller et al.
patent: 5222936 (1993-06-01), Stephen et al.
patent: 5223408 (1993-06-01), Goeddel et al.
patent: 5252479 (1993-10-01), Srivastava
patent: 5286254 (1994-02-01), Shapland et al.
patent: 5288641 (1994-02-01), Roizman
patent: 5324655 (1994-06-01), Kriegler et al.
patent: 5354678 (1994-10-01), Lebkowski et al.
patent: 5399346 (1995-03-01), Anderson et al.
patent: 5422120 (1995-06-01), Kim
patent: 5474935 (1995-12-01), Chatterjee et al.
patent: 5478745 (1995-12-01), Samulski et al.
patent: 5580859 (1996-12-01), Felgner et al.
patent: 6544523 (2003-04-01), Chu
patent: 0675200 (1995-10-01), None
patent: WO 95/13293 (1995-05-01), None
patent: WO 95/21528 (1995-08-01), None
patent: WO 96/03883 (1996-02-01), None
patent: WO 96/34965 (1996-11-01), None
patent: WO 9733617 (1997-09-01), None
Chua A.O. et al. Expression cloning of a human IL-12 receptor component. J. Immunol. 1994. vol. 153, p. 128-136.
Chen Y-T. et al. Expression and localization of two low molecular weight GTP-bidning proteins, Rab8 and Rab10, by epitope tag. Proc. Natl. Acad. Sci. USA. 1993. vol. 90, No. 8, p. 6508-6512.
Malik P. et al. Retroviral-mediated gene expression in human myelomonocytic cells: A comparison of hematopoietic cell progenitors to viral promotors. 1995. Blood. vol. 86, No. 8, p. 2993-3005.
Mickle, J.E., et al. Genotype-phenotype relationships in cystic fibrosis. Med. Clin. N. Am. 2000. vol. 84, No. 3, pp. 597-607.
Tanka, et al., Expression of the functional soluble form of human Fas ligand in activated lymphocytes,The EMBO Journal, 14(6):1129-1135 (Mar. 15, 1995).
International Search Report based on PCT/US 97/20864, International Filing Date Nov. 11, 1997.
Barclay, A.N., et al.,The Leucocyte Antigen Factsbook, Academic Press, London, 1993 at pp. 166-167 and 188-189.
Adachi, et al., Targeted mutation in the Fas gene causes hyperplasia in peripheral lymphoid organs and liver,Nature Genetics, 11(3):294-300 (Nov. 1995) (Abstract Only).
Aggarwal, et al., Fas Antigen Signals Proliferation of Normal Human Diploid Fibroblast and Its Mechanism is Different From Tumor Necrosis Factor Receptor,FEBS Lett., 364(1):5-8 (May 1, 1995) (Abstract Only).
Aichele, et al., Peptide-Induced T-Cell Tolerance to Prevent Autoimmune Diabetes in a Transgenic Mouse Model,Proceedings of the National Academy of Sciences of the United States of America, 91(2):444-8 (Jan. 18, 1994) (Abstract Only).
Alexander, et al.,Analysis of Effector Mechanisms in Murine Cardiac Allograft Rejection, Transplant Immunology, 4(1):46-8 (Mar. 1996) (Abstract Only).
Anderson,Acute Kidney Graft Rejection Morphology and Immunology, Apmis. Supplementum, 67:1-35 (1997) (Abstract Only).
Anderson, et al.,Insulin-dependent diabetes in the NOD mouse model. II Beta cell Destruction in Autoimmune Diabetes is a TH2 and not a THI Mediated Event, Autoimmunity, 15(2):113-22 (1993) (Abstract Only).
Aoki, et al., Clonal expansion but lack of subsequient clonal deletion of bacterial superantigen-reactive T cells in murine retroviral infection,Journal of Immunology, 153(8):3611-21 (Oct. 15, 1994) (Abstract Only).
Arase, et al., Fas-Mediated Cytotoxicity by Freshly Isolated Natural Killer Cells,Journal of Experimental Medicine, 181(3):1235-8 (Mar. 1, 1995) (Abstract Only).
Arnold, et al., Vaccine Development for Aids through Molecular Surgery of a Human Common Cold Virus Surface, HIV and AIDS, Pathogenesis, Therapy and Vaccine, L401,UCLA Symposia, (Mar. 31-Apr. 6, 1990) (Abstract Only).
Asahara, et al., Expression of Fas/Fas Ligand and Proto-Oncogenes in Rheumatoid Synovial Tissues, Nippon Rinsho,Japanese Journal of Clinical Medicine, 54(7):1960-4 (Jul. 1996) (Abstract Only).
Asahara, et al,Expression of Fas Antigen and Fas Ligand in the Rheumatoid Synovial Tissue, Clinical Immunology and Immunopathology, 81(1):27-34 (Oct. 1996).
Badley, et al., Upregulation of Fas Ligand Expression by Human Immunodeficiency Virus in Human Macrophages Mediates Apoptosis of Uninfected T Lymphocytes,Journal of Virology, 70(1):199-206 (Jan. 1996) (Abstract Only).
Baker, et al.,Perform and Fas-Mediated Cytotoxic Pathways are not Required for Allogeneic Resistance to Bone Marrow Grafts in Mice, Biol Blood Marrow Transplant, 1(2):69-73 (Dec. 1995) (Abstract Only).
Baker, et al., The role of cell-mediated cytotoxicity in acute GVHD after MHC—matched allogeneic bone marrow transplantation in mice,Journal of Experimental Medicine, 183(6):2645-56 (Jun. 1, 1996) (Abstract Only).
Beilgrau, et al., A role for CD95 ligand in preventing graft rejection,Nature, 377:630-632 (Oct. 19, 1995).
Berke, et al., PEL's and the Perforin and Granzyme Independent Mechanism of CTL-Mediated Lysis,Immunological Reviews, 146:21-31 (Aug. 1995) (Abstract Only).
Berke, Killing Mechanisms of Cytotoxic Lymphocytes,Curr. Opin Hematol, 4(1):32-40 (Jan. 1997).
Berke, The CTL's Kiss of Death,Cell, 81(1):9-12 (Apr. 7, 1995) (Abstract Only).
Berkner, Development of Adenovirus Vectors for the Expression of Heterologous Genes,Biotechniques6(7):616 (1988).
Boise, et al., Receptors that regulate T-cell susceptibility to apoptotic cell death,Annals of the New York Academy of Sciences, 766:70-80 (Sep. 7, 1995) (Abstract Only).
Boldin, et al., A Novel Protein that Interacts with the Death Domain of Fas/APOI Contains a Sequence Motif Related to the Death Domain,Journal of Biological Chemistry, 270(14):7795-8 (Apr. 7, 1995) (Abstract Only).
Bolling, et al., The Time Course of CTLAlg Effect on Cardiac Allograft Rejection,Journal of Surgical Research, 63(1):320-323 (Jun. 1996) (Abstract Only).
Bonomo, et al., Pathogenesis of post-thymeciony autoimmunity. Role of syngeneic MLR-reactive T cells,Journal of Immunology, 154(12):6602-11 (Jun. 15, 1994) (Abstract Only).
Braun, et al., Cytotoxic T cells deficient in both functional fas lingand and perforin show residual cytolytic activity yet lose their capacity to induce lethal acute graft-ve
Alexander Lisa E.
Attwell Gwilym
Harbin Alisa A.
Hissong Bruce D.
Landsman Robert
LandOfFree
Nucleic acids encoding mutant forms of Fas ligand does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Nucleic acids encoding mutant forms of Fas ligand, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nucleic acids encoding mutant forms of Fas ligand will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3932733